Investing
Immunome announces $200 million stock offering
© Reuters.
BOTHELL, Wash. – Immunome, Inc. (NASDAQ:IMNM), a biotechnology firm focusing on cancer therapies, has unveiled plans for a public offering of $200 million in common stock. The company intends to grant underwriters a 30-day option to buy up to an additional 15% of shares sold in the offering. The completion, timing, and terms of the offering are not guaranteed.
J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities are the joint book-running managers, with Wedbush PacGrow as the lead manager. The offering will be made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2024.
Immunome’s portfolio includes a range of modalities targeting cancer, such as antibody-drug conjugates (ADCs), radioligand therapies, immunotherapies, and small molecules. The company employs a proprietary technology to screen and characterize novel antibodies and targets rapidly.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
-
Side Hustles5 days ago
3 Steps You Can’t Miss When Growing Your Business
-
Make Money7 days ago
15 Jobs That Will Shrink the Fastest Over the Next Decade
-
Side Hustles6 days ago
How to Maximize Your Profits With This Annual 8-Step Checklist
-
Passive Income6 days ago
Why Email Marketing Is Still Your Business’s Most Powerful Tool
-
Side Hustles6 days ago
Want to Start a Business? Consider Buying One Instead — Here’s Why.
-
Investing6 days ago
Germany stocks lower at close of trade; DAX down 0.65% By Investing.com
-
Investing7 days ago
Netherlands stocks lower at close of trade; AEX down 0.80% By Investing.com
-
Investing5 days ago
How I Transformed My Business by Letting Go of Low-Value Tasks